Drug Trial Radar · NCT06806033
Evaluate Optimization of CRS Profile for Glofit Monotherapy and Glofit+GemOx in R/R Aggressive B-NHL
Last checked: Nov 20, 2026Latest source record: Nov 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
130
Planned (sponsor's estimate)
Start
Mar 5, 2025
Primary completion
Jul 31, 2029
Study completion Jul 31, 2030
Sponsor
- Lead sponsor
- Hoffmann-La RocheRoche (Genentech) (RHHBY)
- Sponsor type
- Industry
- First posted
- Feb 3, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This Phase II trial evaluates the optimization of the cytokine release syndrome (CRS) profile for glofitamab in combination with gemcitabine and oxaliplatin (Glofit-GemOx) followed by glofitamab monotherapy treatment regimen (Cohort A), and for glofitamab monotherapy (Cohort B) in participants with relapsed or refractory aggressive B-cell Non-Hodgkin's lymphoma. The study utilizes an optimized steroid premedication regimen and monitoring schedule specifically designed to enable the administration of the treatment regimen in an outpatient setting.
Conditions
- Relapsed or Refractory Aggressive B-Cell Non-Hodgkins Lymphoma
Interventions
ObinutuzumabDrug
Participants will receive intravenous (IV) obinutuzumab 7 days prior to the first dose of glofitamab.
GlofitamabDrug
Participants will receive IV glofitamab, both in combination with gemcitabine and oxaliplatin and as monotherapy, for up to 12 cycles (cycle length = 21 days).
GemcitabineDrug
Participants will receive IV gemcitabine in combination with glofitamab and oxaliplatin for up to 8 cycles (cycles length = 21 days).
OxaliplatinDrug
Participants will receive IV oxaliplatin in combination with glofitamab and gemcitabine for up to 8 cycles (cycle length = 21 days).
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of Cytokine Release Syndrome (CRS)Time frame: Up to approximately 5 years
Locations
53 sites in 7 countries. Site status is shown where the registry gives one.
Alaska Oncology & Hematology, LLC
Anchorage, Alaska · Recruiting
Community Cancer Institute (CCI)
Clovis, California · Recruiting
Providence Medical Foundation
Fullerton, California · Recruiting
Los Angeles Cancer Network
Glendale, California · Withdrawn
Valkyrie Clinical Trials
Los Angeles, California · Recruiting
Valkyrie Clinical Trials
Panorama City, California · Recruiting
Zuckerberg San Francisco General Hospital
San Francisco, California · Recruiting
The Lundquist Institute for BioMedical Innovation at Harbor-UCLA Medical Cente
Torrance, California · Recruiting
Rocky Mountain Cancer Centers, LLP
Aurora, Colorado · Recruiting
North Florida/ South Georgia VA Medical Center
Gainesville, Florida · Withdrawn
Mount Sinai Comprehensive Cancer Center
Miami, Florida · Recruiting
Orlando Health Cancer Institute
Orlando, Florida · Recruiting
St Luke?s Cancer Institute
Boise, Idaho · Recruiting
Cancer Care Specialists of Central Illinois
Swansea, Illinois · Recruiting
Mission Blood and Cancer - MercyOne Cancer Center
Waukee, Iowa · Recruiting
University of Kentucky - Markey Cancer Center
Lexington, Kentucky · Recruiting
Mary Bird Perkins Cancer Ctr
Baton Rouge, Louisiana · Recruiting
Boston Medical Center
Boston, Massachusetts · Recruiting
Corewell Health
Grand Rapids, Michigan · Recruiting
Nebraska Cancer Specialists
Omaha, Nebraska · Recruiting
New York Oncology Hematology, P.C.
Albany, New York · Recruiting
Hematology Oncology Associates of Central New York
East Syracuse, New York · Recruiting
Oncology Associates of Oregon, P.C
Eugene, Oregon · Recruiting
Providence Portland Medical Center
Portland, Oregon · Recruiting
Providence St. Vincent Medical Center
Portland, Oregon · Recruiting
Tennessee Oncology
Chattanooga, Tennessee · Recruiting
Tennessee Oncology
Nashville, Tennessee · Recruiting
Baylor Scott & White Health
Temple, Texas · Recruiting
Texas Oncology - Gulf Coast
The Woodlands, Texas · Recruiting
Texas Oncology- Northeast Texas
Tyler, Texas · Recruiting
Virginia Cancer Specialists, PC
Fairfax, Virginia · Recruiting
Virginia Oncology Associates - Virginia Beach
Virginia Beach, Virginia · Recruiting
Northwest Medical Specialties
Tacoma, Washington · Recruiting
Epworth Hospital
East Melbourne, Victoria, Australia · Recruiting
Arthur J.E. Child Comprehensive Cancer Center
Calgary, Alberta, Canada · Recruiting
CancerCare Manitoba (CCMB)
Winnipeg, Manitoba, Canada · Recruiting
CHU de Grenoble
La Tronche, France · Recruiting
Chu de Montpellier-St Eloi
Montpellier, France · Recruiting
CHU de Bordeaux
Pessac, France · Recruiting
CHU DE RENNES - CHU Pontchaillou
Rennes, France · Withdrawn
Showing 40 of 53 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.